![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BIOSANTE PHARMACEUTICALS TO PRESENT POSITIVE STUDY RESULTS FOR POTENTIAL ADJUVANTED BIRD FLU VACCINE
BIOSANTE PHARMACEUTICALS TO PRESENT POSITIVE STUDY RESULTS FOR POTENTIAL ADJUVANTED BIRD FLU VACCINE
May 8, 2006
BioSante Pharmaceuticals, Inc. today announced that it will present positive
results of several pre-clinical studies, demonstrating that its calcium phosphate
(CaP) nanoparticle-based vaccine adjuvant, BioVant, may serve as an adjuvant
for the development of an effective flu virus vaccine, including the potentially
pandemic H5N1 bird flu.
Genetic
Engineering News
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct